<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUPRAX- cefixime powder, for suspension </strong><br>Lupin Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SUPRAX safely and effectively. See full prescribing information for SUPRAX.<br>Suprax (cefixime) Tablets USP, 400 mg<br>Suprax (cefixime) Capsules, 400 mg<br>Suprax (cefixime) Chewable Tablets, 100 mg, 150 mg and 200 mg<br>Suprax (cefixime) for Oral Suspension USP, 100 mg/5 mL<br>Suprax (cefixime) for Oral Suspension USP, 200 mg/5 mL<br>Suprax (cefixime) for Oral Suspension USP, 500 mg/5 mL<br><br>For oral administration<br><br>Initial U.S. Approval: 1986<br><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Suprax and other antibacterial drugs, Suprax should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Suprax (cefixime) is a cephalosporin antibacterial drug indicated for </p>
<ul class="Disc">
<li>  Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> (<a href="#ID84">1.1</a>)</li>
<li>  <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> (<a href="#ID86">1.2</a>)</li>
<li>  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> (<a href="#ID88">1.3</a>)</li>
<li>  Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> (<a href="#ID90">1.4</a>)</li>
<li>  Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> (cervical/urethral) (<a href="#ID92">1.5</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>  Adults: 400 mg daily (<a href="#ID98">2.1</a>)</li>
<li>  Children: 8 mg/kg/day (<a href="#ID100">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>  Film-coated, scored Tablets: 400 mg (<a href="#ID112">3</a>)</li>
<li>  Capsules: 400 mg (<a href="#ID112">3</a>)</li>
<li>  Chewable Tablets: 100 mg, 150 mg and 200 mg (<a href="#ID112">3</a>)</li>
<li>  Oral Suspension: 100 mg/5 mL, 200 mg/5 mL and 500 mg/5 mL (<a href="#ID112">3</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>  Contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to cefixime or other cephalosporins. (<a href="#ID118">4</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities have been reported with cefixime. Discontinue use if a reaction occurs. (<a href="#ID124">5.1</a>)</li>
<li>  <span class="Italics">Clostridium difficile </span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#ID126">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are gastrointestinal such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (16%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (7%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (6%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (3%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#ID136">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharma at 1-800-399-2561 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>  Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. (<a href="#ID144">7.1</a>)</li>
<li>  Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, with or without clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, has been reported when cefixime is administered concomitantly with warfarin and anticoagulants. (<a href="#ID146">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>  Pregnancy: Cefixime should be used during pregnancy only if clearly needed. (<a href="#ID153">8.1</a>)</li>
<li>  Nursing Mothers: Consideration should be given to discontinuing nursing temporarily during treatment with cefixime. (<a href="#ID157">8.3</a>)</li>
<li>  Children: Efficacy and safety in infants aged less than six months have not been established. (<a href="#ID159">8.4</a>)</li>
<li>  Geriatric Use: Clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. (<a href="#ID161">8.5</a>)</li>
<li>  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Cefixime may be administered in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Dose adjustment is required in patients whose creatinine clearance is less than 60 mL/min. (<a href="#ID163">8.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.2" class="toc">1.1 Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.4 Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span></a></h2>
<h2><a href="#section-1.6" class="toc">1.5 Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> (cervical/urethral)</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients (6 months or older)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Reconstitution Directions for Oral Suspension</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Dose Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Coagulation Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Development of Drug-Resistant Bacteria</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Carbamazepine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Warfarin and Anticoagulants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID81"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID82"></a><a name="section-1.1"></a><p></p>
<p class="First"><a name="ID83"></a>To reduce the development of drug resistant bacteria and maintain the effectiveness of Suprax (cefixime) and other antibacterial drugs, Suprax should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Suprax (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible isolates of the designated bacteria:</p>
</div>
<div class="Section">
<a name="ID84"></a><a name="section-1.2"></a><p></p>
<h2>1.1 Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First"><a name="ID85"></a>Uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> caused by <span class="Italics">Escherichia coli</span> and <span class="Italics">Proteus mirabilis</span>.</p>
</div>
<div class="Section">
<a name="ID86"></a><a name="section-1.3"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></h2>
<p class="First"><a name="ID87"></a><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> caused by <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span>, and <span class="Italics">Streptococcus pyogenes.</span> (Efficacy for <span class="Italics">Streptococcus pyogenes</span> in this organ system was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.)</p>
<p>Note: For patients with <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> caused by <span class="Italics">Streptococcus pneumoniae</span>, overall response was approximately 10% lower for cefixime than for the comparator. [See <span class="Bold">CLINICAL STUDIES</span> <span class="Bold">(<a href="#ID188">14</a>)]</span>. </p>
</div>
<div class="Section">
<a name="ID88"></a><a name="section-1.4"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></h2>
<p class="First"><a name="ID89"></a><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> caused by <span class="Italics">Streptococcus pyogenes.</span> (Note: Penicillin is the usual drug of choice in the treatment of <span class="Italics">Streptococcus pyogenes</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Suprax is generally effective in the eradication of <span class="Italics">Streptococcus pyogenes</span> from the nasopharynx; however, data establishing the efficacy of Suprax in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> is not available.)</p>
</div>
<div class="Section">
<a name="ID90"></a><a name="section-1.5"></a><p></p>
<h2>1.4 Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span></h2>
<p class="First"><a name="ID91"></a>Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span> caused by <span class="Italics">Streptococcus pneumoniae</span> and <span class="Italics">Haemophilus influenzae.</span></p>
</div>
<div class="Section">
<a name="ID92"></a><a name="section-1.6"></a><p></p>
<h2>1.5 Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> (cervical/urethral)</h2>
<p class="First"><a name="ID93"></a>Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> (cervical/urethral) caused by <span class="Italics">Neisseria gonorrhoeae</span> (penicillinase-and non-penicillinase-producing isolates). </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID97"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="ID98"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults</h2>
<p class="First"><a name="ID99"></a>The recommended dose of cefixime is 400 mg daily. This may be given as a 400 mg tablet or capsule daily or the 400 mg tablet may be split and given as one half tablet every 12 hours. For the treatment of uncomplicated cervical/urethral gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a single oral dose of 400 mg is recommended. The capsule and tablet may be administered without regard to food. </p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Streptococcus pyogenes</span>, a therapeutic dosage of cefixime should be administered for at least 10 days.</p>
</div>
<div class="Section">
<a name="ID100"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients (6 months or older)</h2>
<p class="First"><a name="ID101"></a>The recommended dose is 8 mg/kg/day of the suspension. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours. </p>
<p>Note: A suggested dose has been determined for each pediatric weight range. Refer to Table 1. Ensure all orders that specify a dose in milliliters include a concentration, because Suprax for oral suspension is available in three different concentrations (100 mg/5 mL, 200 mg/5 mL, and 500 mg/5 mL).</p>
<a name="ID102"></a><table width="100%">
<caption><span>Table 1. Suggested doses for pediatric patients</span></caption>
<col width="18%">
<col width="12%">
<col width="18%">
<col width="16%">
<col width="14%">
<col width="22%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The preferred concentrations of oral suspension to use are 100 mg/5 mL or 200 mg/5 mL for pediatric patients in these weight ranges.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="6" valign="top">
<span class="Bold">PEDIATRIC </span><span class="Bold">DOSAGE </span><span class="Bold">CHART</span><span class="Bold"><br></span>Doses are suggested for each weight range and rounded for ease of administration<span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Suprax </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold">for </span><span class="Bold">Oral </span><span class="Bold">Suspension</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Suprax </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold">Chewable </span><span class="Bold">Tablet</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">100 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">200 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="1" valign="top">
<span class="Bold">500 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="1" valign="top"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Patient </span><span class="Bold">Weight</span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">kg</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><span class="Bold">/</span><span class="Bold">Day </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mg</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><span class="Bold">/</span><span class="Bold">Day </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><span class="Bold">/</span><span class="Bold">Day </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><span class="Bold">/</span><span class="Bold">Day </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Dose</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5 to 7.5<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.6 to 10<a href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">80<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10.1 to 12.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">100<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet of 100 mg<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12.6 to 20.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">150<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet of 150 mg<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20.6 to 28<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">200<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet of 200 mg<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">28.1 to 33<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">250<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet of 100 mg and <br>1 tablet of 150 mg<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33.1 to 40<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">300<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2 tablets of 150 mg<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40.1to 45<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">350<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet of 150 mg and <br>1 tablet of 200 mg<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">45.1 or greater<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">400<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2 tablets of 200 mg<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID103"></a>Children weighing more than 45 kg or older than 12 years should be treated with the recommended adult dose. Suprax (cefixime) Chewable Tablets must be chewed or crushed before swallowing.</p>
<p><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span> should be treated with the chewable tablets or suspension. Clinical trials of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were conducted with the chewable tablets or suspension, and the chewable tablets or suspension results in higher peak blood levels than the tablet when administered at the same dose. </p>
<p>Therefore, the tablet or capsule should not be substituted for the chewable tablets or suspension in the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. [See <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#ID176">12.3</a>)</span>]</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Streptococcus pyogenes</span>, a therapeutic dosage of cefixime should be administered for at least 10 days.</p>
</div>
<div class="Section">
<a name="ID104"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="ID105"></a>Suprax may be administered in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Refer to Table 2 for dose adjustments for adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Neither hemodialysis nor peritoneal dialysis removes significant amounts of drug from the body.</p>
<a name="ID106"></a><table width="101%">
<caption><span>Table 2. Doses for Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<col width="21%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>The preferred concentrations of oral suspension to use are 200 mg/5 mL or 500 mg/5 mL for patients with this renal dysfunction</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">Renal </span><span class="Bold">Dysfunction </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Suprax </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold">for </span><span class="Bold">Oral </span><span class="Bold">Suspension</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Tablet</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Chewable </span><span class="Bold">Tablet</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Creatinine Clearance (mL/min)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">100 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">200 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">500 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">5 </span><span class="Bold">mL</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">400 </span><span class="Bold">mg</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">200 </span><span class="Bold">mg</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose/Day <br>(mL)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose/Day <br>(mL)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose/Day <br>(mL)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose/Day<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dose/Day<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">60 or greater<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Normal dose<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Normal dose<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Normal dose<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Normal dose<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Normal dose<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">21 to 59<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a><br>OR renal hemodialysis<a href="#footnote-2" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Not Appropriate<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Not Appropriate<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">20 or less <br>OR continuous peritoneal <br>dialysis <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8.6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5 tablet<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1 tablet<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID107"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Reconstitution Directions for Oral Suspension</h2>
<a name="ID108"></a><table width="99%">
<col width="18%">
<col width="11%">
<col width="70%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Strength</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Bottle </span><span class="Bold">Size</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Reconstitution </span><span class="Bold">Directions</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">100 mg/5 mL and <br>200 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">100 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">68 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">100 mg/5 mL and <br>200 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">75 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">51 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">100 mg/5 mL and <br>200 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">50 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">34 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">200 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">37.5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">26 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">200 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">25 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">17 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">500 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">20 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">14 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">500 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">10 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">To reconstitute, suspend with <span class="Bold">8 </span><span class="Bold">mL </span><span class="Bold">water</span>. <br>Method: Tap the bottle several times to loosen powder contents prior to reconstitution. <br>Add approximately half the total amount of water for reconstitution and shake well. <br>Add the remainder of water and shake well.<br>
</td>
</tr>
</tbody>
</table>
<p class="First"><a name="ID109"></a>After reconstitution, the suspension may be kept for 14 days either at room temperature, or under refrigeration, without significant loss of potency. Keep tightly closed. Shake well before using. Discard unused portion after 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID112"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID113"></a><a name="section-3.1"></a><p></p>
<p class="First"><a name="ID114"></a>Suprax is available for oral administration in the following dosage forms and strengths:</p>
<ul class="Disc">
<li>  Film-coated tablets provide 400 mg of cefixime as trihydrate. These are white to off-white, film-coated, capsule shaped tablets with beveled edges and a divided score line on each side. The tablet is debossed with "SUPRAX" across one side and "LUPIN" across the other side.</li>
<li>  Capsules provide 400 mg of cefixime as trihydrate. These are size "00EL" capsules with pink opaque cap and pink opaque body with "LU" on the cap and "U43" on the body in black ink. Capsules contain white to yellowish white granular powder.</li>
<li>  Chewable tablets provide either 100 mg or 150 mg or 200 mg of cefixime as trihydrate. The 100 mg tablet is pink, round tablet, debossed with "SUPRAX 100" on one side and "LUPIN" on other side. The 150 mg tablet is pink, round tablet, debossed with "SUPRAX 150" on one side and "LUPIN" on other side. The 200 mg tablet is pink, round tablet, debossed with "SUPRAX 200" on one side and "LUPIN" on other side.</li>
<li>  Powder for oral suspension, when reconstituted, provides either 100 mg/5 mL or 200 mg/5 mL or 500 mg/5 mL of cefixime as trihydrate. For 100 mg/5 mL and 200 mg/5 mL, the powder has an off white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow color and is strawberry flavored. For 500 mg/5 mL, the powder has an off white to cream color and is strawberry flavored.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID118"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID119"></a><a name="section-4.1"></a><p></p>
<p class="First"><a name="ID120"></a>Suprax<span class="Sup"> </span>(cefixime) is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to cefixime or other cephalosporins.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID123"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="ID124"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><a name="ID125"></a>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities) have been reported with the use of cefixime. </p>
<p>Before therapy with Suprax is instituted, careful inquiry should be made to determine whether the patient has had previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to cephalosporins, penicillins, or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Suprax occurs, discontinue the drug. </p>
</div>
<div class="Section">
<a name="ID126"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Clostridium difficile-Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><a name="ID127"></a><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Suprax, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile.</span></p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of <span class="Italics">C.</span> <span class="Italics">difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile, </span>and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section">
<a name="ID128"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Dose Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="ID129"></a>The dose of Suprax should be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD). Patients on dialysis should be monitored carefully [See <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#ID97">2</a>)</span>].</p>
</div>
<div class="Section">
<a name="ID130"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Coagulation Effects</h2>
<p class="First"><a name="ID131"></a>Cephalosporins, including Suprax, may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</p>
</div>
<div class="Section">
<a name="ID132"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Development of Drug-Resistant Bacteria</h2>
<p class="First"><a name="ID133"></a>Prescribing Suprax (cefixime) in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID136"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section">
<a name="ID137"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><a name="ID138"></a>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most commonly seen adverse reactions in U.S. trials of the tablet formulation were gastrointestinal events, which were reported in 30% of adult patients on either the twice daily or the once daily regimen. Five percent (5%) of patients in the U.S. clinical trials discontinued therapy because of drug-related adverse reactions. Individual adverse reactions included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 16%, loose or frequent stools 6%, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> 3%, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 7%, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> 3%, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> 4%. The incidence of gastrointestinal adverse reactions, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients receiving tablets.</p>
</div>
<div class="Section">
<a name="ID139"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First"><a name="ID140"></a>The following adverse reactions have been reported following the use of cefixime. Incidence rates were less than 1 in 50 (less than 2%).</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal</span></span></p>
<p>Several cases of documented <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> were identified in clinical trials. The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after therapy.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></span></p>
<p>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatalities), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions have been reported.</p>
<p><span class="Bold"><span class="Italics">Hepatic</span></span></p>
<p>Transient elevations in SGPT, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Bold"><span class="Italics">Renal</span></span></p>
<p>Transient elevations in BUN or creatinine, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p><span class="Bold"><span class="Italics">Central Nervous System</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Bold"><span class="Italics">Hemic and Lymphatic System</span></span></p>
<p>Transient <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, prolongation in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, elevated LDH, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold"><span class="Italics">Abnormal Laboratory Tests</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>.</p>
<p><span class="Bold"><span class="Italics">Other Adverse Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">Genital pruritus</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold"><span class="Italics">Adverse Reactions Reported for Cephalosporin-class Drugs</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced. [See <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#ID97">2</a>) </span>and<span class="Bold"> OVERDOSAGE (<a href="#ID167">10</a></span>)]. If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID143"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section">
<a name="ID144"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Carbamazepine</h2>
<p class="First"><a name="ID145"></a>Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.</p>
</div>
<div class="Section">
<a name="ID146"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Warfarin and Anticoagulants</h2>
<p class="First"><a name="ID147"></a>Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, with or without clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, has been reported when cefixime is administered concomitantly.</p>
</div>
<div class="Section">
<a name="ID148"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drug/Laboratory Test Interactions</h2>
<p class="First"><a name="ID149"></a>A false-positive reaction for <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.</p>
<p>The administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest<span class="Sup">®</span>**, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix<span class="Sup">®</span>** or TesTape<span class="Sup">®</span>**) be used. A false-positive direct Coombs test has been reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug.</p>
<p>**Clinitest<span class="Sup">®</span> and Clinistix<span class="Sup">®</span> are registered trademarks of Ames Division, Miles Laboratories, Inc. Tes-Tape<span class="Sup">®</span> is a registered trademark of Eli Lilly and Company.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID152"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID153"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="ID154"></a>Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of harm to the fetus due to cefixime. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID155"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First"><a name="ID156"></a>Cefixime has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID157"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="ID158"></a>It is not known whether cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID159"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="ID160"></a>Safety and effectiveness of cefixime in children aged less than six months old have not been established. The incidence of gastrointestinal adverse reactions, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, in the pediatric patients receiving the suspension, was comparable to the incidence seen in adult patients receiving tablets.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID161"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="ID162"></a>Clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. A pharmacokinetic study in the elderly detected differences in pharmacokinetic parameters [See <span class="Bold">CLINICAL PHARMACOLOGY (<a href="#ID176">12.3</a>)</span>]. These differences were small and do not indicate a need for dosage adjustment of the drug in the elderly.</p>
</div>
<div class="Section">
<a name="ID163"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="ID164"></a>The dose of cefixime should be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD). Patients on dialysis should be monitored carefully [See <span class="Bold">DOSAGE AND ADMINISTRATION (<a href="#ID104">2.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID167"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><a name="ID168"></a>Gastric lavage may be indicated; otherwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse reactions in small numbers of healthy adult volunteers receiving single doses up to 2 g of cefixime did not differ from the profile seen in patients treated at the recommended doses.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID169"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><a name="ID170"></a>Cefixime is a semisynthetic, cephalosporin antibacterial for oral administration. Chemically, it is (<span class="Italics">6R,7R</span>)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 7<span class="Sup">2</span>-(<span class="Italics">Z</span>)-[<span class="Italics">O</span>-(carboxy methyl) oxime] trihydrate.</p>
<p>Molecular weight = 507.50 as the trihydrate. Chemical Formula is C<span class="Sub">16</span>H<span class="Sub">15</span>N<span class="Sub">5</span>O<span class="Sub">7</span>S<span class="Sub">2</span>.3H<span class="Sub">2</span>O</p>
<p>The structural formula for cefixime is:</p>
<div class="Figure"><img alt="Cefixime USP" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2462b2-bfed-4da4-8c47-46838d6153f8&amp;name=73b4ac79-6e4f-464e-853c-eab65a8b7a38-01.jpg"></div>
<ul class="Disc">
<li>  Inactive ingredients contained in Suprax<span class="Bold"><span class="Sup">®</span></span>  (cefixime) 400 mg tablets are: dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, titanium dioxide, and triacetin.</li>
<li>  Inactive ingredients contained in Suprax<span class="Bold"><span class="Sup">®</span></span>  (cefixime) 400 mg capsules are: colloidal silicon dioxide, crospovidone, low substituted hydroxy propyl cellulose, magnesium stearate, and mannitol. The capsule shell contains the following inactive ingredients: ferric oxide black, ferric oxide red, gelatin, potassium hydroxide, propylene glycol, shellac, sodium lauryl sulfate, and titanium dioxide.</li>
<li>  Inactive ingredients contained in Suprax<span class="Bold"><span class="Sup">®</span></span>  (cefixime) 100 mg or 150 mg or 200 mg chewable tablets are: aspartame, colloidal silicon dioxide, crospovidone, FD&amp;C Red # 40 Aluminium Lake, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, fantasy flavor permaseal, and tutti frutti flavor.</li>
<li>  Inactive ingredients contained in Suprax<span class="Bold"><span class="Sup">®</span></span>  (cefixime) powder for oral suspension are: colloidal silicon dioxide, sodium benzoate, strawberry flavor, sucralose (only in 500 mg/5 mL strength), sucrose, and xanthan gum.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID173"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID174"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="ID175"></a>Cefixime is a semisynthetic cephalosporin antibacterial drug [see <span class="Bold">Microbiology</span> <span class="Bold">(<a href="#ID180">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID176"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="ID177"></a>Suprax chewable tablets are bioequivalent to oral suspension. </p>
<p>Suprax tablets and suspension, given orally, are about 40% to 50% absorbed whether administered with or without food; however, time to maximal absorption is increased approximately 0.8 hours when administered with food. A single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2 mcg/mL (range 1 to 4 mcg/mL); a single 400 mg tablet produces an average peak concentration of approximately 3.7 mcg/mL (range 1.3 to 7.7 mcg/mL). The oral suspension produces average peak concentrations approximately 25% to 50% higher than the tablets, when tested in normal <span class="Italics">adult</span> volunteers. Two hundred and 400 mg doses of oral suspension produce average peak concentrations of 3 mcg/mL (range 1 to 4.5 mcg/mL) and 4.6 mcg/mL (range 1.9 to 7.7 mcg/mL), respectively, when tested in normal <span class="Italics">adult</span> volunteers. The area under the time versus concentration curve (AUC) is greater by approximately 10% to 25% with the oral suspension than with the tablet after doses of 100 to 400 mg, when tested in normal <span class="Italics">adult</span> volunteers. This increased absorption should be taken into consideration if the oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, tablets should not be substituted for oral suspension in the treatment of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> [See<span class="Bold"> DOSAGE AND ADMINISTRATION (<a href="#ID97">2</a></span><span class="Bold">)</span>]. Cross-over studies of tablet versus suspension have not been performed in children.</p>
<p>The 400 mg capsule is bioequivalent to the 400 mg tablet under fasting conditions. However, food reduces the absorption following administration of the capsule by approximately 15% based on AUC and 25% based on C<span class="Sub">max</span>.</p>
<p>Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet, a single 400 mg tablet or 400 mg of cefixime suspension. Peak serum concentrations occur between 2 and 5 hours following a single administration of 200 mg of suspension. Peak serum concentrations occur between 3 and 8 hours following oral administration of a single 400 mg capsule.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Serum protein binding is concentration independent with a bound fraction of approximately 65%. In a multiple dose study conducted with a research formulation which is less bioavailable than the tablet or suspension, there was little accumulation of drug in serum or urine after dosing for 14 days. Adequate data on CSF levels of cefixime are not available.</p>
<p><span class="Bold"><span class="Italics">Metabolism and Excretion</span></span></p>
<p>There is no evidence of metabolism of cefixime<span class="Italics"> in vivo.</span> Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may range up to 9 hours in some normal volunteers.</p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<p><span class="Bold"><span class="Italics">Geriatrics: </span></span>Average AUCs at steady state in elderly patients are approximately 40% higher than average AUCs in other healthy adults. Differences in the pharmacokinetic parameters between 12 young and 12 elderly subjects who received 400 mg of cefixime once daily for 5 days are summarized as follows:</p>
<a name="ID178"></a><table width="100%">
<col width="34%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Difference between age groups was significant. (p&lt;0.05)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Pharmacokinetic </span><span class="Bold">Parameters </span><span class="Bold">(</span><span class="Bold">mean </span><span class="Bold">± </span><span class="Bold">SD</span><span class="Bold">) </span><span class="Bold">for </span><span class="Bold">Cefixime </span><span class="Bold">in </span><span class="Bold">Both </span><span class="Bold">Young </span><span class="Bold">&amp; </span><span class="Bold">Elderly </span><span class="Bold">Subjects</span><span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Pharmacokinetic </span><span class="Bold">parameter</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Young</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Elderly</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> (mg/L)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.74 ± 1.43<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5.68 ± 1.83<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">T<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> (h)<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.9 ± 0.3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.3 ± 0.6<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">AUC (mg.h/L)<a href="#footnote-3" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">34.9 ± 12.2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">49.5 ± 19.1<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">T<span class="Sub">½</span> (h)<a href="#footnote-3" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.5 ± 0.6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.2 ± 0.4<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">C<span class="Sub">a</span><span class="Sub">v</span><span class="Sub">e</span> (mg/L)<a href="#footnote-3" class="Sup">*</a><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.42 ±0.50<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.99 ± 0.75<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID179"></a>However, these increases were not clinically significant [See <span class="Bold">DOSAGE AND ADMINISTRATION</span> <span class="Bold">(<a href="#ID97">2</a>)</span>].  </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span></span>In subjects with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis. However, a study indicated that with doses of 400 mg, patients undergoing hemodialysis have similar blood profiles as subjects with creatinine clearances of 21 to 60 mL/min.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="ID180"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><a name="ID181"></a>Mechanism of Action</p>
<p>Bactericidal action of cefixime results from inhibition of cell-wall synthesis. </p>
<p>Cefixime has been shown to be active against most isolates of the following bacteria both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [see <span class="Bold">INDICATIONS AND USAGE (<a href="#ID81">1</a>)</span>]:</p>
<p>Gram-positive bacteria</p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p>Gram-negative bacteria</p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Moraxella catarrhalis</span></p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown. Suprax exhibits <span class="Italics">in vitro</span> MICs of 1 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of Suprax in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled clinical trials. </p>
<p>Gram-positive bacteria</p>
<p><span class="Italics">Streptococcus agalactiae</span></p>
<p>Gram-negative bacteria</p>
<p><span class="Italics">Haemophilus parainfluenzae</span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Klebsiella oxytoca</span></p>
<p><span class="Italics">Pasteurella multocida</span></p>
<p><span class="Italics">Providencia </span>species</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>species</p>
<p><span class="Italics">Shigella </span>species</p>
<p><span class="Italics">Citrobacter amalonaticus</span></p>
<p><span class="Italics">Citrobacter diversus</span></p>
<p><span class="Italics">Serratia marcescens</span></p>
<p><span class="Bold"><span class="Italics">Susceptibility</span> <span class="Italics">Tests Methods</span></span></p>
<p>When available, the clinical microbiology laboratory should provide the results of<span class="Italics"> in vitro</span> susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<p><span class="Bold"><span class="Italics">Dilution Techniques: </span></span>Quantitative methods are used to determine the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using standardized test methods <span class="Sup">1,2</span> (broth, and/or agar). The MIC values should be interpreted according to the criteria in Table 3.</p>
<p><span class="Bold"><span class="Italics">Diffusion Techniques: </span></span>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using standardized method.<span class="Sup">2,3</span> This procedure uses paper disks impregnated with 5 mcg of cefixime to test the susceptibility of bacteria to cefixime. The disk diffusion interpretive criteria are provided in Table 3.</p>
<a name="ID182"></a><table width="98%">
<caption><span>Table 3: Susceptibility interpretive criteria for cefixime</span></caption>
<col width="26%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Insufficient information is available to determine  Intermediate or Resistant interpretive criteria</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">Pathogen</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Minimum </span><span class="Bold">Inhibitory </span><span class="Bold">Concentrations </span><span class="Bold">(</span><span class="Bold">mcg</span><span class="Bold">/</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Disk </span><span class="Bold">Diffusion </span><span class="Bold">Zone </span><span class="Bold">Diameter </span><span class="Bold">(</span><span class="Bold">mm</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">S</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">I</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">R</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">S</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">I</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">R</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Neisseria </span><span class="Italics">gonorrhoeae</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤ 0.25<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥ 31<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">H</span><span class="Italics">. </span><span class="Italics">influenzae</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥21<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">E</span><span class="Italics">. </span><span class="Italics">coli </span>and <span class="Italics">P</span><span class="Italics">. </span><span class="Italics">mirabilis</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤ 1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥ 4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≥ 19<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16 - 18<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">≤ 15<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID183"></a>A report of "Susceptible" indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of "Intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
<p><span class="Bold"><span class="Italics">Quality Control</span></span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.<span class="Sup">1, 2, 3</span> The standard cefixime powder should provide the following range of MIC values provided in Table 4. For the diffusion technique using the 5-mcg cefixime disk the criteria provided in Table 4 should be achieved.</p>
<a name="ID184"></a><table width="99%">
<caption><span>Table 4: Acceptable Quality Control Ranges for Susceptibility Testing</span></caption>
<col width="31%">
<col width="37%">
<col width="31%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Quality </span><span class="Bold">Control </span><span class="Bold">Organisms</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Minimum </span><span class="Bold">Inhibitory </span><span class="Bold">Concentrations </span><span class="Bold">(</span><span class="Bold">mcg</span><span class="Bold">/</span><span class="Bold">mL</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Disk </span><span class="Bold">Diffusion </span><span class="Bold">(</span><span class="Bold">zone </span><span class="Bold">diameters </span><span class="Bold">in </span><span class="Bold">mm</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">E</span><span class="Italics">. </span><span class="Italics">coli </span>ATCC 25922<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.25 - 1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23 - 27<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">aureus </span>ATCC 29213<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8 - 32<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">--<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">H</span><span class="Italics">. </span><span class="Italics">influenzae </span>ATCC 49247<span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.12-1<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25-33<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">N</span><span class="Italics">. </span><span class="Italics">gonorrhoeae </span>ATCC 49226<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.004 - 0.03<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37 - 45<br>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID185"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID186"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First"><a name="ID187"></a>Lifetime studies in animals to evaluate carcinogenic potential have not been conducted. Cefixime did not cause point mutations in bacteria or mammalian cells, DNA damage, or chromosome damage <span class="Italics">in vitro</span> and did not exhibit clastogenic potential <span class="Italics">in vivo</span> in the mouse micronucleus test. In rats, fertility and reproductive performance were not affected by cefixime at doses up to 25 times the adult therapeutic dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID188"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><a name="ID189"></a>Comparative clinical trials of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were conducted in nearly 400 children between the ages of 6 months to 10 years. <span class="Italics">Streptococcus pneumoniae</span> was isolated from 47% of the patients, <span class="Italics">Haemophilus influenzae</span> from 34%, <span class="Italics">Moraxella catarrhalis</span> from 15% and <span class="Italics">S. pyogenes</span> from 4%.</p>
<p>The overall response rate of <span class="Italics">Streptococcus pneumoniae</span> to cefixime was approximately 10% lower and that of <span class="Italics">Haemophilus influenzae</span> or <span class="Italics">Moraxella  catarrhalis</span> approximately 7% higher (12% when beta-lactamase positive isolates of <span class="Italics">H. influenzae</span> are included) than the response rates of these organisms to the active control drugs.</p>
<p>In these studies, patients were randomized and treated with either cefixime at dose regimens of 4 mg/kg twice a day or 8 mg/kg once a day, or with a comparator. Sixty-nine to 70% of the patients in each group had resolution of signs and symptoms of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> when evaluated 2 to 4 weeks post-treatment, but persistent <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> was found in 15% of the patients. When evaluated at the completion of therapy, 17% of patients receiving cefixime and 14% of patients receiving effective comparative drugs (18% including those patients who had <span class="Italics">Haemophilus influenzae</span> resistant to the control drug and who received the control antibiotic) were considered to be treatment failures. By the 2 to 4 week follow-up, a total of 30%-31% of patients had evidence of either treatment failure or recurrent disease.</p>
<a name="ID190"></a><table width="100%">
<col width="34%">
<col width="23%">
<col width="21%">
<col width="22%">
<tfoot>
<tr class="First"><td align="left" colspan="4"><p class="First Footnote">(a)Number eradicated/number isolated.<br></p></td></tr>
<tr class="Last"><td align="left" colspan="4"><p class="First Footnote">(b)An additional 20 beta-lactamase positive isolates of <span class="Italics">Haemophilus </span><span class="Italics">influenzae </span>were isolated, but were excluded from this analysis because they were resistant to the control antibiotic. In nineteen of these, the clinical course could be assessed and a favorable outcome occurred in 10. When these cases are included in the overall bacteriological evaluation of therapy with the control drugs, 140/185 (76%) of pathogens were considered to be eradicated.<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="justify" colspan="4" valign="top">
<span class="Bold">Bacteriological </span><span class="Bold">Outcome </span><span class="Bold">of </span><span class="Bold">Otitis </span><span class="Bold">Media </span><span class="Bold">at </span><span class="Bold">Two </span><span class="Bold">to </span><span class="Bold">Four </span><span class="Bold">Weeks </span><span class="Bold">Post</span><span class="Bold">-</span><span class="Bold">Therapy </span><span class="Bold">Based </span><span class="Bold">on </span><span class="Bold">Repeat </span><span class="Bold">Middle </span><span class="Bold">Ear </span><span class="Bold">Fluid </span><span class="Bold">Culture </span><span class="Bold">or </span><span class="Bold">Extrapolation </span><span class="Bold">from </span><span class="Bold">Clinical </span><span class="Bold">Outcome</span><span class="Bold"><br></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Organism</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cefixime</span><span class="Bold">(</span><span class="Bold">a</span><span class="Bold">)</span><span class="Bold"><br></span><span class="Bold">4 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">kg </span><span class="Bold">BID</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Cefixime</span><span class="Bold">(</span><span class="Bold">a</span><span class="Bold">)</span><span class="Bold"><br></span><span class="Bold">8 </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">kg </span><span class="Bold">QD</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Control</span><span class="Bold">(</span><span class="Bold">a</span><span class="Bold">)</span><span class="Bold"><br></span><span class="Bold">drugs</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Streptococcus </span><span class="Italics">pneumoniae</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">48/70 (69%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18/22 (82%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">82/100 (82%)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Haemophilus </span><span class="Italics">influenzae</span><span class="Italics"><br></span>beta-lactamase negative<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">24/34 (71%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13/17 (76%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23/34 (68%)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Haemophilus </span><span class="Italics">influenzae</span><span class="Italics"><br></span>beta-lactamase positive<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17/22 (77%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9/12 (75%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1/1 (b)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">Moraxella </span><span class="Italics">catarrhalis</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">26/31 (84%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5/5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18/24 (75%)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Italics">S</span><span class="Italics">. </span><span class="Italics">pyogenes</span><span class="Italics"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5/5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3/3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6/7<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">All Isolates<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">120/162 (74%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">48/59 (81%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">130/166 (78%)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID191"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Clinical and Laboratory Standards Institute (CLSI) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard-9th Edition. CLSI Document M07-A9. CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing 21st Informational Supplement, CLSI document M100-S22,CLSI, 2012.</li>
<li>CLSI. Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests. Approved Standard-11<span class="Sup">th</span>Edition, CLSI document M02-A11, 2012.</li>
<li>Faulkner RD, Bohaychuk W, Lanc RA, et al.: Pharmacokinetics of cefixime in the young and elderly.<span class="Italics">J Antimicrob Chemother</span>1988; 21(6): 787-794.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID193"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="ID194"></a>Suprax<span class="Sup">®</span> is available for oral administration in following dosage forms, strengths and packages listed in the table below:</p>
<a name="ID195"></a><table width="100%">
<col width="15%">
<col width="12%">
<col width="27%">
<col width="12%">
<col width="12%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Dosage </span><span class="Bold">Form</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Strength</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Description</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Package </span><span class="Bold">Size</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">NDC </span><span class="Bold">Code</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Storage</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">White to off-white, <br>film-coated, capsule <br>shaped tablets with <br>beveled edges and <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottles of <br>10 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-201-10<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Suprax</span><span class="Bold"><span class="Sup">®</span> </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold"><br></span><span class="Bold">Tablets </span><span class="Bold">USP</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="left" valign="middle">400 mg<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">a divided score <br>line on each side, <br>debossed with “SUPRAX? <br>across one side <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-201-08<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Store at 20 to 25°C <br>(68 to 77°F) <br>[See USP Controlled <br>Room Temperature].<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle">and “LUPIN? across <br>other side, containing <br>400 mg of cefixime<br> as the trihydrate.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>100 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-201-01<br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Suprax</span><span class="Bold"><span class="Sup">®</span> </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold"><br></span><span class="Bold">Capsules</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">400 mg<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">Size “00EL? capsules with <br>pink opaque cap and pink <br>opaque body, imprinted <br>with “LU? on cap and <br>“U43? on body in black <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 capsules<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-208-08<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">Store at 20 to 25°C <br>(68 to 77°F) <br>[See USP Controlled <br>Room Temperature].<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle">ink, containing white to <br>yellowish white granular <br>powder containing <br>400 mg of cefixime as the <br>trihydrate.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Unit Dose <br>Package of 10<br>(1 blister of <br>10 capsules)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-208-11<br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottles of <br>10 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-203-10<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule" align="left" valign="middle">100 mg<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Pink, round tablet, <br>debossed with “SUPRAX 100? <br>on one side and “LUPIN? <br>on other side.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-203-08<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Unit Dose <br>Package of 10<br>(1 blister of <br>10 tablets)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-203-11<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottles of <br>10 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-204-10<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Suprax</span><span class="Bold"><span class="Sup">®</span> </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold"><br></span><span class="Bold">Chewable </span><span class="Bold">Tablets</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="left" valign="middle">150 mg<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Pink, round tablet, <br>debossed with “SUPRAX 150? <br>on one side and “LUPIN? <br>on other side.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-204-08<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Store at 20 to 25°C <br>(68 to 77°F) <br>[See USP Controlled <br>Room Temperature].<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Unit Dose <br>Package of 10<br>(1 blister of <br>10 tablets)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-204-11<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottles of <br>10 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-205-10<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule" align="left" valign="middle">200 mg<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Pink, round tablet, <br>debossed with “SUPRAX 200? <br>on one side and “LUPIN? <br>on other side.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 tablets<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-205-08<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Unit Dose <br>Package of 10<br>(1 blister of <br>10 tablets)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-205-11<span class="Underline"><br></span>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">Off-white to pale <br>yellow colored powder. <br>After reconstituted as <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">68180-202-03<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"> <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule" align="left" valign="middle">100 mg/5 mL<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">directed, each 5 mL of <br>reconstituted suspension <br>contains 100 mg of <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>75 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">68180-202-02<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"> <br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle">cefixime as the trihydrate.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>100 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">68180-202-01<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>25 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-206-05<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>37.5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-206-06<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Underline">Prior </span><span class="Underline">to </span><span class="Underline">reconstitution</span>: <br>Store drug powder at<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Suprax</span><span class="Bold"><span class="Sup">®</span> </span><span class="Bold">(</span><span class="Bold">cefixime</span><span class="Bold">) </span><span class="Bold"><br></span><span class="Bold">for </span><span class="Bold">Oral </span><span class="Bold"><br></span><span class="Bold">Suspension </span><span class="Bold">USP</span><span class="Bold"><br></span>
</td>
<td class="Lrule Rrule" align="left" valign="middle">200 mg/5 mL<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Off-white to pale <br>yellow colored powder. <br>After reconstituted as <br>directed, each 5 mL of<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>50 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-206-03<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">20 to 25°C (68 to 77°F) <br>[See USP Controlled <br>Room Temperature].<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule" align="left" valign="middle">reconstituted suspension <br>contains 200 mg of <br>cefixime as the trihydrate.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>75 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-206-02<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Underline">After </span><span class="Underline">reconstitution</span>: <br>Store at room temperature <br>or under refrigeration.<br>Keep tightly closed.<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>100 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-206-01<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">500 mg/5 mL<br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle">Off white to cream <br>colored powder forming <br>off-white to pale yellow <br>suspension with <br>characteristic fruity odor <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>10 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-207-02<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Botrule Lrule Rrule" align="left" valign="middle">on constitution. After <br>reconstituted as directed,<br>each mL of reconstituted <br>suspension contains <br>100 mg of cefixime <br>as the trihydrate.<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Bottle of <br>20 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">27437-207-03<br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID196"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID197"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<p class="First"><a name="ID198"></a>Patients should be counseled that antibacterial drugs, including cefixime, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cefixime is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefixime for oral suspension or cefixime chewable tablets or other antibacterial drugs in the future.</p>
<p><span class="Bold">Phenylketonurics: Suprax<span class="Sup"> </span>(cefixime) Chewable Tablets contains 3.3 mg, 5 mg and 6.7 mg of phenylalanine per 100 mg, 150 mg and 200 mg strength, respectively.</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<a name="ID199"></a><table width="100%">
<col width="55%">
<col width="27%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Products</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Manufactured </span><span class="Bold">for</span><span class="Bold">:</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Manufactured </span><span class="Bold">by</span><span class="Bold">:</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) Tablets USP, 400 mg <br>
</td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule Toprule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) Capsules, 400 mg <br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Lupin </span><span class="Bold">Pharma</span><br>
</td>
<td class="Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) Chewable Tablets, 100 mg, 150 mg and 200 mg<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Baltimore, Maryland 21202<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">
<span class="Bold">Lupin </span><span class="Bold">Limited</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) for Oral Suspension USP, 200 mg/5 mL<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">United States.<br>
</td>
<td class="Lrule Rrule" align="left" valign="middle">Mandideep 462 046<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) for Oral Suspension USP, 500 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
<td class="Lrule Rrule" align="left" valign="middle">India.<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Suprax<span class="Sup">®</span> (cefixime) for Oral Suspension USP, 100 mg/5 mL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Lupin </span><span class="Bold">Pharmaceuticals</span><span class="Bold">, </span><span class="Bold">Inc</span><span class="Bold">.</span><span class="Bold"><br></span>Baltimore, Maryland 21202<br>United States.<br>
</td>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><br></td>
</tr>
</tbody>
</table>
<p><a name="ID200"></a>Revised: March 15<span class="Sup">th</span>, 2013                                                                              ID#: 231653</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID201"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><a name="ID202"></a><span class="Bold">SUPRAX<span class="Sup">®</span> CEFIXIME FOR ORAL SUSPENSION USP</span></p>
<p>100 mg/5 mL</p>
<p>Rx only</p>
<p>NDC 68180-202-03: Bottle of 50 mL</p>
<div class="Figure"><img alt="SUPRAX CEFIXIME FOR ORAL SUSPENSION USP
100 mg/5 mL
Rx only
							NDC 68180-202-03: Bottle of 50 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2462b2-bfed-4da4-8c47-46838d6153f8&amp;name=73b4ac79-6e4f-464e-853c-eab65a8b7a38-02.jpg"></div>
<p><a name="ID204"></a><span class="Bold">SUPRAX<span class="Sup">®</span> CEFIXIME FOR ORAL SUSPENSION USP</span></p>
<p>100 mg/5 mL</p>
<p>Rx only</p>
<p>NDC 68180-202-04: Bottle of 10 mL (Physician Sample Pack)</p>
<p>NDC 68180-202-05: Carton for 10 mL x 6 Bottles (Physician Sample Pack)</p>
<div class="Figure"><img alt="SUPRAX CEFIXIME FOR ORAL SUSPENSION USP
100 mg/5 mL
Rx only
							NDC 68180-202-04: Bottle of 10 mL (Physician Sample Pack)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2462b2-bfed-4da4-8c47-46838d6153f8&amp;name=73b4ac79-6e4f-464e-853c-eab65a8b7a38-03.jpg"></div>
<div class="Figure"><img alt="SUPRAX CEFIXIME FOR ORAL SUSPENSION USP
100 mg/5 mL
Rx only
							NDC 68180-202-05: Carton for 10 mL x 6 Bottles (Physician Sample Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2462b2-bfed-4da4-8c47-46838d6153f8&amp;name=73b4ac79-6e4f-464e-853c-eab65a8b7a38-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUPRAX 		
					</strong><br><span class="contentTableReg">cefixime powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68180-202</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFIXIME</strong> (CEFIXIME ANHYDROUS) </td>
<td class="formItem">CEFIXIME ANHYDROUS</td>
<td class="formItem">100 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STRAWBERRY</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (off-white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68180-202-03</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:68180-202-02</td>
<td class="formItem">75 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:68180-202-01</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:68180-202-05</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:68180-202-04</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065129</td>
<td class="formItem">03/01/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lupin Pharmaceuticals, Inc.
							(089153071)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>LUPIN LIMITED (675923163)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">LUPIN LIMITED</td>
<td class="formItem"></td>
<td class="formItem">725504448</td>
<td class="formItem">manufacture(68180-202)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>73b4ac79-6e4f-464e-853c-eab65a8b7a38</div>
<div>Set id: 7e2462b2-bfed-4da4-8c47-46838d6153f8</div>
<div>Version: 3</div>
<div>Effective Time: 20140908</div>
</div>
</div> <div class="DistributorName">Lupin Pharmaceuticals, Inc.</div></p>
</body></html>
